Muroi Masashi, Tanamoto Ken-ichi
National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya, Tokyo 158-8501, Japan.
J Leukoc Biol. 2008 Mar;83(3):702-7. doi: 10.1189/jlb.0907629. Epub 2007 Dec 10.
MyD88 and IL-1R-associated kinase 1 (IRAK-1) play crucial roles as adaptor molecules in signal transduction of the TLR/IL-1R superfamily, and it is known that expression of these proteins leads to the activation of NF-kappaB in a TNFR-associated factor 6 (TRAF6)-dependent manner. We found in this study, however, that a dominant-negative mutant of TRAF6, lacking the N-terminal RING and zinc-finger domain, did not inhibit IRAK-1-induced activation of NF-kappaB in human embryonic kidney 293 cells, although the TRAF6 mutant strongly suppressed the MyD88-induced activation. The dominant-negative mutant of TRAF6 did not affect the IRAK-1-induced activation, regardless of the expression level of IRAK-1. In contrast, small interfering RNA silencing of TRAF6 expression inhibited MyD88-induced and IRAK-1-induced activation, and supplementation with the TRAF6 dominant-negative mutant did not restore the IRAK-1-induced activation. Expression of IRAK-1, but not MyD88, induced the oligomerization of TRAF6, and IRAK-1 and the TRAF6 dominant-negative mutant were associated with TRAF6. These results indicate that TRAF6 is involved but with different mechanisms in MyD88-induced and IRAK-induced activation of NF-kappaB and suggest that TRAF6 uses a distinctive mechanism to activate NF-kappaB depending on signals.
髓样分化因子88(MyD88)和白细胞介素-1受体相关激酶1(IRAK-1)作为衔接分子在Toll样受体/白细胞介素-1受体(TLR/IL-1R)超家族的信号转导中发挥关键作用,并且已知这些蛋白的表达以肿瘤坏死因子受体相关因子6(TRAF6)依赖的方式导致核因子κB(NF-κB)的激活。然而,我们在本研究中发现,缺乏N端环和锌指结构域的TRAF6显性负性突变体,虽然强烈抑制MyD88诱导的激活,但并不抑制IRAK-1在人胚肾293细胞中诱导的NF-κB激活。无论IRAK-1的表达水平如何,TRAF6显性负性突变体均不影响IRAK-1诱导的激活。相反,TRAF6表达的小干扰RNA沉默抑制了MyD88诱导的和IRAK-1诱导的激活,并且补充TRAF6显性负性突变体不能恢复IRAK-1诱导的激活。IRAK-1而非MyD88的表达诱导了TRAF6的寡聚化,并且IRAK-1和TRAF6显性负性突变体与TRAF6相关联。这些结果表明,TRAF6参与了MyD88诱导的和IRAK诱导的NF-κB激活,但机制不同,提示TRAF6根据信号利用独特的机制激活NF-κB。